Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-20-019815
Filing Date
2020-04-29
Accepted
2020-04-29 17:28:40
Documents
11
Period of Report
2020-06-23
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A acad-def14a_20200623.htm DEF 14A 2363947
2 GRAPHIC g3oc11uxinni000002.jpg GRAPHIC 7571
3 GRAPHIC g3oc11uxinni000040.jpg GRAPHIC 10005
4 GRAPHIC g3oc11uxinni000003.jpg GRAPHIC 2405
5 GRAPHIC g3oc11uxinni000001.jpg GRAPHIC 67957
6 GRAPHIC g3oc11uxinni000004.jpg GRAPHIC 7860
7 GRAPHIC g3oc11uxinni000079.jpg GRAPHIC 87345
8 GRAPHIC g3oc11uxinni000080.jpg GRAPHIC 81320
9 GRAPHIC g3oc11uxinni000005.jpg GRAPHIC 147254
10 GRAPHIC g3oc11uxinni000065.jpg GRAPHIC 2607
11 GRAPHIC g3oc11uxinni000041.jpg GRAPHIC 10843
  Complete submission text file 0001564590-20-019815.txt   2945671
Mailing Address 3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130 858-558-2871
ACADIA PHARMACEUTICALS INC (Filer) CIK: 0001070494 (see all company filings)

EIN.: 061376651 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50768 | Film No.: 20831893
SIC: 2834 Pharmaceutical Preparations